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Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a
laparoscopic technique for local chemotherapy. It has been used for treatment of
peritoneal metastasis of gastric cancer (PM GC) in combination with systemic therapy.
VEGFR2 antagonist ramucirumab is a second-line therapy for GC, and has been
suspected to cause wound healing disorders.
Methods: This is a retrospective single center cohort study of patients with PM GC, who
received PIPAC treatment in combination with systemic chemotherapy with and without
ramucirumab. Data on patients’ characteristics and their perioperative courses were
collected and complication rates were compared with regard to preoperative use of
ramucirumab and time between last dose of systemic therapy and PIPAC treatment.
Results: Fifty patients underwent 90 PIPAC treatments for PM GC in 3 years. Overall
postoperative morbidity was 11% with 6% severe complications. The mean interval
between systemic therapy and PIPAC was 20 days. Neither the length of interval nor the
use of ramucirumab had an effect on complication rates.
Conclusion: Our study suggests that addition of ramucirumab to pre-PIPAC systemic
therapy, irrespective of the length of the treatment-free interval before PIPAC, does not
increase the risk of postoperative complications and is therefore a safe option for
treatment of PM GC.
Keywords: gastric cancer, peritoneal metastasis, pressurized intraperitoneal aerosol chemotherapy, ramucirumab,
peritoneal chemotherapyApril 2021 | Volume 10 | Article 6105721
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Although its incidence slowly decreases in Western countries,
gastric cancer (GC) still remains the third most frequent cancer
related cause of death worldwide (1). In 5–20% of all GC
patients, peritoneal metastasis (PM) is found at the time of
diagnosis and up to 40% of stage II-III GC patients present
PM during abdominal exploration (2). PM of gastric origin is
associated with poor median survival rates of only 3 to 7 months
without treatment (3, 4) and represents cause of death in 60% of
GC patients (5).
Gastrectomy in a multimodal treatment strategy with
perioperative chemotherapy is a curative treatment option for
patients with locally advanced GC, including those with limited
PM, in selected cases (6–8). The value of additional hyperthermic
intraperitoneal chemotherapy (HIPEC) in order to prevent or
delay peritoneal recurrence is controversially discussed and is
currently subject of various randomized controlled trials (7, 9).
However, studies suggest that a careful patient selection is
fundamental, and only patients with a limited peritoneal tumor
spread, defined as a peritoneal cancer index (PCI) of under 6–12,
may benefit from cytoreductive surgery (CRS) including
gastrectomy and peritonectomy (10, 11).
Patients with more advanced peritoneal tumor burden, who
do not qualify for CRS and HIPEC, should receive systemic
chemotherapy as soon as possible as it was shown to significantly
increase survival, longer sustain a good quality of life, and better
control symptoms (12). First-line therapy according to recent
evidence should be a triple combination of fluorouracil (5-FU)
plus leucovorin, oxaliplatin and docetaxel, (FLOT), whenever the
patient is fit for this treatment (13), or else a double combination
of oxaliplatin or cisplatin and 5-FU plus leucovorin (FLO) (14).
Following the results of the RAINBOW study, anti-vascular
endothelial growth factor receptor 2 (VEGFR2) antibody
ramucirumab as monotherapy or in combination with
paclitaxel has been approved as second line chemotherapy in
Germany and other countries (12, 15).
Common systemic chemotherapy, however, is associated with
severe adverse side effects such as neutropenia, diarrhea, and
polyneuropathy (8, 12). Addition of ramucirumab and other
angiogenesis inhibitors, such as bevacizumab, to chemotherapy
has been shown to add toxicity, specifically the risk of
hypertension, bleeding, and impaired wound healing (16).
Besides the risk of adverse effects, according to pre-clinical
studies, systemic chemotherapy might display limited
penetration of the sparsely vascularized peritoneum (17–20).
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
represents a novel approach to efficiently deliver chemotherapeutic
agents directly to the peritoneumand thus reduce systemic side effect
for patients, and potentially increase the cytotoxic efficacy. Based on
the concept of therapeutic pneumoperitoneum, which was first
described by Reymond in 2000 (21), PIPAC has been shown to
potentially stabilize PM and even lead to histologic tumor regression
in some patients (22). Others have suggested PIPAC as a potential
option to reduce the Peritoneal Carcinomatosis Index (PCI) in order
to facilitate CRS and HIPEC, in a neoadjuvant setting (23). Most
institutions perform PIPAC in alternation with first, second, third orFrontiers in Oncology | www.frontiersin.org 2even fourth line intravenous chemotherapy in an effort to achieve
optimal control of disease usingbidirectional (systemicplus regional)
cytotoxic approach (24, 25). Ramucirumab in combination with
paclitaxel offers a survival benefit as second line treatment for GC
patients and has therefore been reportedly used as intermittent
chemotherapy regimen for PIPAC patients in some centers (25, 26).
As systemic chemotherapy, especially with addition of
angiogenesis inhibition has been shown to impact wound
healing (8, 27), it is common practice to maintain a certain wash
out period prior to PIPAC in order to reduce the risk of systemic
chemotherapy induced postoperative complications. Study
protocols of current randomized clinical trials testing the
addition of PIPAC to systemic chemotherapy propose an
interval of 14 days (28, 29). This is also the interval that has
been reportedly used by several PIPAC centers, including ours
(26, 30). However, this is not in accordance with current
recommendations that suggest to withhold ramucirumab at least
28 days before surgery (16). The optimal time interval between
systemic chemotherapy with or without angiogenesis inhibitors
and PIPAC in terms of both efficacy and safety has not been
studied specifically and thus remains unclear (24).
The purpose of this study is to determine the safety of PIPAC
surgery following VEGFR2 antagonist ramucirumab containing
chemotherapy as a second line treatment for peritoneal
metastasis of gastric cancer.MATERIALS AND METHODS
Data Collection
We retrospectively reviewed clinical data of all patients who
underwent PIPAC for PM of GC at the Department of Surgery,
Campus Charité Mitte and Campus Virchow-Klinikum, Charité
Universitätsmedizin Berlin, between March 2017 and May 2020.
Oncological history and prior treatments including detailed
chemotherapy regimens were collected at initial consultation.
Follow-up consultation was regularly performed at our institute.
After PIPAC treatment, follow-up data were additionally
obtained from medical oncologists or general practitioners.
The last date of follow-up was the 09th of April 2020. All
included patients gave informed consent to collection of their
personal and medical data and its use for research purposes. All
data were collected, stored, and processed according to General
Data Protection Regulation and local data protection laws. The
study was conducted in accord with the ethical standards of the
Helsinki Declaration of 1975.
Clinical Parameters and Classifications
The preoperative general status of our patients was assessed
using the American Society for Anesthesiologists physical
status classification (ASA) and the Eastern Cooperative
Oncology Group performance status (ECOG). Postoperative
complications were categorized according to the Clavien-
Dindo classification (31). Standard laboratory tests were
performed pre- and postoperatively, including blood count and
serum concentrations of creatinine and transaminases. SurgicalApril 2021 | Volume 10 | Article 610572
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disease control) classification as superficial incisional SSI (I),
deep incisional SSI (II), or organ/space SSI (III). Acute kidney
injury network (AKIN) criteria were used for the classification of
post-PIPAC acute kidney injury, defining acute kidney injury as
increase of baseline serum creatinine by 1.5 fold or ≥0.3 mg/dl
(32). Nodal status was either determined by a radiologist using
preoperative computed tomography (CT) scans or, in case of
patients who underwent gastrectomy previously, by the staff
pathologist as part of the TNM tumor classification.
Indication for PIPAC Treatment
The indication for every PIPAC procedure was discussed and
confirmed individually by our multidisciplinary tumor board
specialized on peritoneal malignancies. Patients were offered
PIPAC procedure if they had histologically proven gastric
cancer with suspected or verified PM, no other distant
metastasis (except for Krukenberg tumors of the ovary), had
an ECOG performance status of 2 or better, had completed at
least one line of systemic chemotherapy without disease
progression and were not considered for CRS and HIPEC (6).
Informed consent was obtained from all patients before surgery,
and included comprehensive information about the pending
validation of the method in controlled clinical studies as well
as alternative treatments such as systemic (second to forth line)
chemotherapy alone.
Pre- and Post-PIPAC Chemotherapy
The pre- and post-PIPAC chemotherapeutic regimen was
individually decided by the treating medical oncologists, in
concert with recommendations of our multidisciplinary tumor
board, and based on co-morbidities, adverse side effects, previous
chemotherapeutic regimens, and possible inclusion in clinical
studies. We proposed three intermittent PIPAC treatments with
a 2-week interval between applications of intravenous and
intraperitoneal chemotherapy. Between two PIPAC surgeries,
we recommended two cycles of systemic therapy (28, 29).
PIPAC Procedure
PIPAC was performed by a small team of specialized surgeons.
The standard operating procedure that we established and
followed at our center was based on publications by other
institutions (33–35). Drugs administered were cisplatin at a
dosage of 7.5 mg/m2 and doxorubicin at 1.5 mg/m2, each
dissolved in 150 ml NaCl. In brief, diagnostic laparoscopy was
performed after introduction of two 12 mm trocars. Ascites, if
present, was extracted for cytological analysis, and peritoneal
tissue samples for histopathological examination were resected
from PM. The PCI was assessed according to Jacquet and
Sugarbaker (36), and documented by a short video for future
comparison. Then the nebulizer (Capnopen™, Capnomed
GmbH, Villingendorf, Germany) was introduced and
connected with an angiographic injector (Medrad Arterion
Mark 7, Leverkusen, Germany). After the staff left the
operating room the aerosol was commenced with a maximum
pressure of 200 psi and a flow rate of 0.5 ml/min.Frontiers in Oncology | www.frontiersin.org 3The patients were mobilized and allowed to eat and drink on
the day of surgery. Analgesics as well as antiemetics were
prescribed routinely as follows: for analgesia paracetamol or
metamizole (1 g every 8 or 6 h, respectively, intravenously), if
necessary complemented by piritramide for acute postoperative
pain (7.5 mg subcutaneously) and oxycodone/sustained release
(10 mg every 12 h orally) for prolonged or pre-existing pain;
for antiemesis ondansetron (4 mg every 6 h intravenously or
orally), if necessary complemented by droperidol (1.25 mg
intravenously) on demand. In absence of complications,
patients were routinely discharged from the hospital on the
second or third postoperative day.
Statistics
Microsoft Excel version 2006 and IBM SPSS 26th Edition (IBM,
Armonk, NY, USA) were used for initial data collection and
statistical analysis, respectively. Continuous variables were
expressed as median (range), and compared with Mann-
Whitney U-test. The Shapiro-Wilk test and the Levene test
were used to test for normal distribution and homogeneity of
variance, respectively. The frequencies of categorical variables
were compared using Fisher’s exact test. Binary logistic
regression analysis was used to test the effect of a continuous
variable on a categorical dependent variable. A value of p < 0.05
was considered significant.RESULTS
Number of Sequential PIPAC Treatments
and Reasons for Discontinuation
Between March of 2017 and May of 2020, 50 patients with PM
GC received at least one PIPAC at our center, amounting to a
total of 90 PIPAC treatments. Half of the 50 patients who
received one PIPAC treatment underwent a second PIPAC and
13 patients (26%) completed three sequential treatments. Two
patients (4%) had four PIPACs. Among the 37 patients who did
not complete the intended three treatment cycles, but quit after
one or after two PIPACs, the most common reason was cancer
progress. Other reasons were preference of patient or treating
medical oncologist or difficult access due to peritoneal adhesions,
as determined in the first or second treatment. In five cases
(10%), patients were allocated to CRS and HIPEC subsequent to
PIPAC treatment. Reasons for discontinuation of PIPAC
treatment are displayed in Table 1.TABLE 1 | Reasons for completing less than three cycles of PIPAC treatments.
Reason for discontinuation No. of patients (%) (n = 37)
Tumor progress/tumor complications 17 (45)
Preference of patient/medical oncologist 7 (19)
Subsequent CRS+HIPEC 5 (14)
Difficult access (adhesions) 4 (11)
Death 4 (11)April 2021 | Volume 10 | Article 610572
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Characteristics
Clinical baseline characteristics of our patients and details of
their oncological history are summarized in Table 2. Patients
were a median 58 (31–76) years old at the time of the first
PIPAC, slightly more likely to be male (n = 28, 55%), and the
majority had an impaired general physical status according to
ASA classification (n = 29, 58% ASA 3). On the ECOG scale for
patient performance, the majority of patients (n = 41, 82%) had a
good status of 0 or 1.
With respect to the histological type of gastric cancer, our
cohort was relatively homogeneous: 43 patients (88%) were
identified as diffuse type according to the Laurén classification;
for 35 of them (70% of all), the tumor contained signet ring cells.
Four patients (8%) presented ovarian metastases. While the
majority of patients (n = 35, 70%) were reportedly nodal
positive, 15 patients (30%) were declared as N0, either by
preoperative CT scan or by the pathologist after initial
gastrectomy. At the time of the first PIPAC treatment, median
PCI was 19, but showed substantial variation (range 1–39).Frontiers in Oncology | www.frontiersin.org 4History of Previous Gastrectomy, CRS,
and HIPEC
In our cohort, 30 patients (60%) had synchronous PM while 20
(40%) developed PM after initial diagnosis of GC. Of the 20 cases
with metachronous PM, 17 patients previously underwent
gastrectomy with curative intent. The other three patients were
diagnosed with PM after neoadjuvant chemotherapy, and
therefore did not receive the intended gastrectomy. Of the 30
patients with synchronous PM, six patients also underwent
gastrectomy before first PIPAC: five gastrectomies were
performed in combination with CRS with or without HIPEC
as an individualized treatment concept for limited, synchronous
PM, and one patient received palliative gastrectomy for tumor
bleeding. Three patients had received HIPEC without CRS prior
to first PIPAC treatment.
Figure 1 visualizes these different clinical and treatment
courses of our GC patients with PM depending on the order of
diagnosis. Numbers of chemotherapy and PIPAC cycles varied
widely and are depicted symbolically.
Length of Stay and Postoperative
Complication Rates
The median duration of a PIPAC procedure was 75 min (37–
116). The length of surgery did not differ between the first or any
of the subsequent PIPACs. Patients stayed a median of three
nights (2–43) in the hospital before discharge. The length of stay
(LOS) did not change with the number of PIPAC treatments.
Out of 90 performed PIPACs, patients only stayed longer than
five nights in five cases (6%), four of which were due to additional
treatments of their underlying tumors: endoscopy for bleeding of
the primary tumor (in two cases) and pleurodesis for pleural
effusion (2nd and 3rd PIPAC treatments of the same patient). The
fifth case was due to bowel perforation which caused several re-
operations and an extended hospital stay of 43 nights.
Out of 90 PIPACs, there was one case (1%) of stage 1 acute
kidney injury as defined by the AKIN criteria. This male patient
had an increased postoperative serum creatinine level that was
1.6-fold his preoperative value, but that was still in the normal
range (1.01 mg/dl) and decreased to baseline levels under
conservative treatment. There was no significant change in
serum levels of alanine aminotransferase (ALT) before and
after PIPAC treatment in any case, indicating no relevant
hepatic parenchymal injury.
Overall postoperative morbidity was 11% (10 cases), and
severe complications as assessed by Clavien-Dindo classification
of grade three or more, were reported in five cases (6%). Four
patients were re-admitted to the hospital after initial discharge
due to complications, and four patients underwent re-operation.
All postoperative complications, their management, and re-
admissions are detailed in Table 3.
History of Chemotherapies
All patients in our cohort underwent at least one line of
chemotherapy before their first PIPAC treatment. However, as
our cohort comprises both patients with metachronous PM and









Sex (female) 22 (45%)
ASA 1 2 (4%)
2 19 (38%)
3 29 (58%)
ECOG 0 20 (40%)
1 21 (42%)
2 9 (18%)
Histological type (Laurén) intestinal type 4 (8%)
diffuse type 44 (88%)
mixed type 1 (2%)
missing data 1 (2%)
Presence of signet cells 35 (70%)




Synchronous PM 30 (60%)
Metachronous PM 20 (40%)
Metastasis to the ovary 4 (8%)
Gastrectomy gastrectomy before PIPAC 23 (46%)
curative intent* 17 (34%)
with CRS +/− HIPEC† 5 (10%)
palliative 1 (2%)
no gastrectomy before PIPAC 27 (54%)
HIPEC without CRS (pre-PIPAC) 3 (6%)
PCI (median, min-max) 19 (1–39)ASA, American Society for Anesthesiologists physical status; ECOG, Eastern Cooperative
Oncology Group performance status; PCI, peritoneal cancer index; CRS, cytoreductive
surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; PIPAC, pressurized
intraperitoneal aerosol chemotherapy; PM, peritoneal metastasis. *no PM at diagnosis;
†CRS +/− HIPEC as individualized, curative treatment for synchronous, limited PM.April 2021 | Volume 10 | Article 610572
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length, number of treatments, and treatment intention (curative
vs. palliative). To examine the impact of prior systemic
chemotherapy with or without ramucirumab on the safety of
PIPAC treatment, we have analyzed the last systemic therapy
patients received before PIPAC procedure, which is detailed in
Table 4. For this analysis, we did not consider any therapies that
were administered more than 6 weeks (42 days) prior to PIPAC.Frontiers in Oncology | www.frontiersin.org 5This selection excluded 13 cases (14%), thus leaving 77 PIPACs
(86%) to be analyzed for pre-PIPAC systemic therapies and their
relation with postoperative complications.
The last treatment before PIPAC included ramucirumab in 35
cases (45%), most commonly in combination with paclitaxel.
Most patients who did not receive ramucirumab, were treated




FIGURE 1 | Schematic treatment courses of patients with gastric cancer and metachronous (A) or synchronous (B, C) peritoneal metastasis. Numbers and
regimens of chemotherapies and numbers of PIPACs varied between patients and are depicted symbolically. *diagnosis of PM at the time of intended curative
gastrectomy, which was then aborted. †patients who received CRS+/−HIPEC after first or second PIPAC treatment. GC, gastric cancer; PM, peritoneal metastasis;
CTx, chemotherapy; CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; PIPAC, pressurized intraperitoneal aerosol chemotherapy.TABLE 3 | Postoperative complications and re-admissions after PIPAC treatments.
Severity No. of cases (%) (n = 90) Type of complication Treatment Reason for re-admission
1 5 (6%) Nausea (n = 2)
Surgical Site Infection Grade I (n = 2)






3a 1 (1%) Surgical Site Infection Grade III (n = 1) Interventional drainage n = 1
3b 4 (4%) Small bowel perforation (n = 1)
Surgical Site Infection Grade II (n = 1)
Trocar site hernia (n = 1)
Urinary infection + acute abdomen (n = 1)
Re-operation (laparotomy + ileostomy)




for acute abdomen; no pathological




4-5 0April 2021 |Severity classification according to Clavien-Dindo. Surgical Site Infection grades according to CDC classification.Volume 10 | Article 610572
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regimen that patients received prior to PIPAC surgery was two
(1–10). The number depended significantly on the number of
PIPAC surgery: patients received a median of four cycles (1–10)
before their first PIPAC treatment, while the median number of
cycles between PIPAC treatments was two (1–2; p < 0.001).
Addition of Ramucirumab Does Not
Increase Postoperative Complication
Rates
Out of the 35 PIPACs that were performed within 42 days after
the administration of ramucirumab, three cases had
postoperative complications: one SSI, one bowel perforation,
and one case of early postoperative urinary infection that led
to diagnostic laparoscopy for acute abdomen. Comparing
patients who had received ramucirumab before PIPAC
treatment with those who had not, there was no significant
difference in overall postoperative morbidity, severe
complication rate, or length of stay, as shown in Table 5.
Shorter Interval Between Systemic
Chemotherapy and PIPAC, Irrespective of
Addition of Ramucirumab, Does Not
Increase Postoperative Complication
Rates
When scheduling procedures, we recommended a pause of at
least 14 days between PIPAC treatment and chemotherapy andFrontiers in Oncology | www.frontiersin.org 6vice versa. In 13 cases, patients of our cohort had received
chemotherapy more than 42 days before a PIPAC treatment
(most commonly before their first PIPAC). These cases excluded,
there was a median of 20 days (7–41) interval between last day of
chemotherapy and PIPAC treatment. Interestingly, patients
treated with an addition of ramucirumab had a significantly
shorter interval between systemic treatment and PIPAC
procedure than patients without ramucirumab (18 days (7–38)
vs 21 days (14–41), p = 0.02).
Patients who received systemic chemotherapy less than 14,
21, or 28 days before PIPAC surgery, respectively, were not more
likely to develop postoperative complications. This was true
irrespective of the addition of ramucirumab to systemic
chemotherapy (Table 6). Days between last dose of systemic
therapy and PIPAC also did not predict postoperative
complications in a logistic regression model (odds ratio 1.038;
95% confidence interval 0.941–1.144; p = 0.458).DISCUSSION
PIPAC is a novel, innovative strategy for intraperitoneal
application of chemotherapy for the treatment of advanced
stages of PM GC. One potential benefit of adding intermittent
local anti-cancer therapy is to bridge longer breaks of systemic
chemotherapy and thus permit a prolonged overall duration of
treatment without adding to systemic toxicity. While large
randomized controlled trials are still lacking, several smaller
observational studies suggest that PIPAC may promote
histological tumor regression, attenuate development of ascites,
improve survival, and might facilitate subsequent CRS and
HIPEC (23, 26, 37).
According to current guidelines, systemic chemotherapy is
essential for the treatment of patients with PM GC, and as
clinical trials have not yet proven the efficacy of PIPAC
treatment, any delay in the administration of systemic
chemotherapy has to be averted. It is therefore crucial to assess
possible effects of preoperative systemic therapies on
postoperative complications and determine the optimal time
interval between systemic chemotherapy and PIPAC. Several
studies have demonstrated that PIPAC is a safe procedure with
low postoperative complication rates (22, 25, 30, 38). However,
most studies comprise heterogeneous groups with different
tumor entities and therefore different preceding systemic
therapies, and do not provide details on preoperative therapies
and time intervals between systemic treatment and PIPAC.
We here report a single-institution cohort of patients that
homogeneously present with PM GC and receive between one
and four PIPAC treatments, with the aim of analyzing their
postoperative complications in relation to their preoperative
systemic treatments. We observe an overall postoperative
morbidity of 11% in PM GC patients after PIPAC with severe
complications in 6%, which is in keeping with other studies (39,
40). Almost half (45%) of systemic therapies obtained within 6
weeks before PIPAC treatments included ramucirumab. In fact,
the median interval between ramucirumab-containing systemicTABLE 4 | History of chemotherapy regimens preceding PIPAC treatment.
No. of cases (%) (n = 77)*




FOLFIRI + ramucirumab 2 (3%)
EOX/ECF/ECX 2 (3%)
Capecitabine/5-FU + FA 4 (5%)
5-FU + ramucirumab 3 (4%)
any chemotherapy without ramucirumab 42 (54.5%)
any chemotherapy with ramucirumab 35 (45.5%)*Cases with more than 42 days interval since last chemotherapy dose (n = 13) were
excluded. FLO, 5-fluorouracil (5-FU) + leucovorin + oxaliplatin; FLOT, FLO+ taxane
(docetaxel); FLT, 5-FU + leucovorin + taxane; FLC, 5-FU + leucovorin + cisplatin; Xelox,
oxapliplatin + capecitabine; EOX, epirubicin + oxaliplatin + capecitabine; ECX, epirubicin +
cisplatin + capecitabine; ECF, epirubicin + cisplatin + 5-FU; FOLFIRI, 5- FU + leucovorin +
irinotecan.TABLE 5 | Effect of ramucirumab (RAM) addition to pre-PIPAC chemotherapy
(CTx) on postoperative complication rates and length of stay (LOS).
CTx - RAM CTx + RAM
(n = 42) (n = 35) p-value
Overall morbidity 4 (10%) 3 (9%) 1.000
Severe complication 2 (5%) 3 (9%) 0.654
LOS (median, min-max) 3 (2-6) 3 (2-43) 0.211Severe complications are classified as Clavien-Dindo ≥3a.April 2021 | Volume 10 | Article 610572
Feldbrügge et al. Ramucirumab and PIPAC for Gastric Cancertreatment and PIPAC was 18 days, and thus 3 days shorter than
that between other chemotherapy and PIPAC. Nevertheless, we
did not observe any increase in complication rates or LOS after
prior treatment with ramucirumab, when compared with
patients who received ramucirumab-free chemotherapy.
Furthermore, regardless of the composition of chemotherapy,
outcomes did not depend on the interval between last dose of
systemic therapy and PIPAC surgery. To date, no study has been
published about the optimal interval between systemic therapy
and PIPAC surgery, especially with a focus on potential adverse
effects of ramucirumab.
Angiogenesis inhibitors that target the formation of aberrant,
pathological vessels by a tumor, have been shown to be effective
anti-cancerous agents. Especially anti-VEGF-A antibody
bevacizumab has become an established component of
systemic anti-cancer therapy for tumors of the brain, lung,
breast, and colorectal cancer (41, 42). However, bevacizumab
was shown to impair wound healing as demonstrated in the
context of colorectal liver metastasis, treated surgically after
neoadjuvant chemotherapy including bevacizumab. This has
led to the official recommendation of delaying surgery for 6
weeks after treatment with bevacizumab (43–45). Eveno et al.
could show that neoadjuvant bevacizumab treatment
significantly increases incidence of major perioperative
complications, wound healing disorders, intraabdominal
abscess formation and leads to longer hospitalization in
colorectal cancer patients undergoing CRS and HIPEC,
although a 6-week wash-out period had been upheld (46). On
the other hand, when focusing on patients with gastro-
esophageal cancers, Okines et al. found that bevacizumab did
not increase perioperative complications including bleeding and
wound healing disorders with 5 to 6 weeks between bevacizumab
and surgery (47).
Anti-VEGFR2 antibody ramucirumab was more recently
added to the portfolio of angiogenesis inhibitors for solid
tumor therapy. Its first FDA approval was passed in 2014 for
second line treatment of advanced gastric cancer (15). Like
bevacizumab, ramucirumab has been associated with an
increased rate of wound healing disorders. However, this
correlation is only based on a total of 18 cases of wound-
healing complications (14 after ramucirumab, 4 in control
groups) in a meta-analysis comprising 4,996 patients (27). Its
effects on perioperative complications, more specifically after
minimally-invasive surgery such as PIPAC have not been studied
to date.Frontiers in Oncology | www.frontiersin.org 7Recently, Siebert et al. described a cohort of 26 patients who
underwent PIPAC procedures after receiving bevacizumab and
compared their complication rates with 108 patients who were
treated without bevacizumab. Interestingly, in this study,
bevacizumab treatment was not associated with increased
perioperative morbidity (48). While this is an important
observation, being the first study that explicitly examines PIPAC
complications after angiogenesis inhibition, it has to be noted that
this study cohort was very heterogeneous, and the bevacizumab
group did not include any patients with gastric cancer.
Furthermore, prior chemotherapies and the time intervals
between systemic therapy and PIPACwere not presented in detail.
While our patient demographics and oncological
classifications are in accordance with other reports about
advanced GC, some characteristics of our cohort should be
pointed out for precise interpretation of the results. First, as
our patient cohort comprises patients with both synchronous
and metachronous peritoneal metastasis, there are substantial
differences in their individual medical history, such as prior
gastrectomy, duration and number of cycles of prior
chemotherapy. These factors are likely to influence survival,
which is why we have not intended, in this cohort, to analyze
survival. However, the influence of ramucirumab or other
chemotherapies on short-term postoperative outcome after
PIPAC is unlikely to be impacted by long-term differences in
medical history, especially since general health, as measured with
ASA and ECOG scores, was very homogeneous in our group.
Only a randomized controlled trial could establish with certainty
that oncological history, prior surgeries, or other, unknown
factors do not have significant influence on chemotherapy
induced perioperative morbidity. The total number of
complications in our cohort is too low for a meaningful
multivariate analysis, that could otherwise strengthen our
results in this regard.
In conclusion, despite these limitations due to the nature of
our retrospective study, we here present the first study that
analyzes safety of PIPAC for peritoneal metastasis of gastric
cancer in combination with systemic therapy including
ramucirumab. Our data suggest that addition of ramucirumab
to systemic therapy, even with a treatment-free interval as short
as 2 weeks before PIPAC surgery, does not increase the risk of
postoperative complications. Still, randomized controlled clinical
trials are urgently needed to confirm efficacy of PIPAC treatment
and ascertain optimal combination and timing of inductive and
intermittent systemic chemotherapy.TABLE 6 | Effect of interval between systemic chemotherapy with or without ramucirumab (+ RAM or – RAM, respectively) and PIPAC on postoperative complication
rates.
Interval (days) ≤14 15–21 22–28 >28
CTx – or + RAM − RAM + RAM − RAM + RAM − RAM + RAM − RAM + RAM
No. of patients n = 2 n = 9 n = 20 n = 17 n = 11 n = 5 n = 8 n = 4
Overall morbidity 1 0 1 1 0 2 2 0
Severe complications 1 0 1 1 0 2 0 0April 2021 | Volume 10 | ArticleSevere complications are classified as Clavien-Dindo ≥3a.610572
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